Education
About Us
Working with TipRanks
Follow Us
XORTX Therapeutics Inc (TSE:XRTX)
:XRTX
XRTX Stock Chart & Stats
C$0.78
C$0.05(2.94%)
At close: 4:00 PM EST
C$0.78
C$0.05(2.94%)
Day’s Range― - ―
52-Week RangeC$0.50 - C$1.97
Previous CloseN/A
Volume514.00
Average Volume (3M)11.08K
Market Cap
C$3.69M
Enterprise Value-C$166.71K
Total Cash (Recent Filing)C$1.66M
Total Debt (Recent Filing)C$82.23K
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Mar 26, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding6,962,218
10 Day Avg. Volume30,736
30 Day Avg. Volume11,079
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA Discussions For Gout TreatmentThe FDA discussions for the XRx-026 program could lead to regulatory approval, potentially transforming XORTX into a revenue-generating company by addressing a significant market need in gout treatment.
Low Debt LevelsLow debt levels provide XORTX with financial flexibility and reduce the risk of financial distress, allowing the company to focus on developing its drug pipeline without significant interest obligations.
Innovative Drug TherapiesXORTX's focus on innovative therapies for chronic diseases like kidney and cardiovascular conditions positions it well in a market with high unmet medical needs, offering potential for long-term growth and market leadership.
Bears Say
No Revenue GenerationThe lack of revenue generation highlights the company's reliance on external funding and underscores the urgency for successful commercialization of its drug candidates to achieve financial sustainability.
Nasdaq Compliance RiskNon-compliance with Nasdaq's minimum bid price requirement poses a risk of delisting, which could limit access to capital markets and negatively impact investor confidence.
Negative Cash FlowSustained negative cash flow reflects ongoing operational challenges and the need for external financing, which could become difficult if investor interest wanes, impacting long-term viability.
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was C$0.50 and its highest was C$1.97 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is C$3.69M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Mar 26, 2026 which is in 31 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on Nov 15, 2025. The company reported -C$0.178 earnings per share for the quarter, beating the consensus estimate of -C$0.228 by C$0.051.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate is -0.23.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 6,962,218 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -C$0.178 in its last earnings report, beating expectations of -C$0.228. Following the earnings report the stock price went down -1.667%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in TSE:XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Kane Biotech
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Options Prices
Currently, No data available
---